The non-live herpes zoster (Shingrix®) vaccine is suggested for all IBD patients who are immunosuppressed, age 18 years and older and is strongly recommended for all IBD patients age 50 and older, whether immunosuppressed or not.
Adults 50 years of age or older:
Persons ≥ 18 years of age who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.
Safety and efficacy in persons younger than 18 years have not been established. The primary vaccination schedule consists of two doses, given 2 to 6 months apart. Immunosuppressed persons can receive the second dose 1 to 2 months after the initial dose.
There is no information on the use of Shingrix® in pregnant or breast-feeding women. Providers should consider delaying vaccination.
Shingrix® can be given concomitantly with unadjuvanted seasonal influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23), or reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap).